skip to main content
Idioma:
Refinado por: Nome da Publicação: The American Heart Journal remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
Material Type:
Artigo 		Adicionar ao Meu Espaço

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

Armstrong, Paul W. ; Adams, Peter X. ; Al-Khalidi, Hussein R. ; Hamm, Christian ; Holmes, David ; O'Neill, William ; Todaro, Thomas G. ; Vahanian, Alec ; Van de Werf, Frans ; Granger, Christopher B.

The American heart journal, 2005-03, Vol.149 (3), p.402-407 [Periódico revisado por pares]

New York, NY: Mosby, Inc

Texto completo disponível

Citações Citado por
2
Bringing cardiovascular cell-based therapy to clinical application: Perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting
Bringing cardiovascular cell-based therapy to clinical application: Perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting
Material Type:
Artigo 		Adicionar ao Meu Espaço

Bringing cardiovascular cell-based therapy to clinical application: Perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting

Jolicoeur, E. Marc, MD, MSc ; Granger, Christopher B., MD ; Fakunding, John L., PhD ; Mockrin, Steven C., PhD ; Grant, Steven M., MD ; Ellis, Stephen G., MD, FACC ; Weisel, Richard D., MD, FACC ; Goodell, Margaret A., PhD

The American heart journal, 2007-05, Vol.153 (5), p.732-742 [Periódico revisado por pares]

New York, NY: Mosby, Inc

Texto completo disponível

Citações Citado por
3
Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF
Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF
Material Type:
Artigo 		Adicionar ao Meu Espaço

Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF

DeVore, Adam D. ; Granger, Bradi B. ; Fonarow, Gregg C. ; Al-Khalidi, Hussein R. ; Albert, Nancy M. ; Lewis, Eldrin F. ; Butler, Javed ; Piña, Ileana L. ; Heidenreich, Paul A. ; Allen, Larry A. ; Yancy, Cyde W. ; Cooper, Lauren B. ; Felker, G. Michael ; Kaltenbach, Lisa A. ; McRae, A. Thomas ; Lanfear, David E. ; Harrison, Robert W. ; Kociol, Robb D. ; Disch, Maghee ; Ariely, Dan ; Miller, Julie M. ; Granger, Christopher B. ; Hernandez, Adrian F.

The American heart journal, 2020-02, Vol.220, p.41-50 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
4
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction
Material Type:
Artigo 		Adicionar ao Meu Espaço

Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction

Armstrong, Paul W. ; Mahaffey, Kenneth W. ; Chang, Wei-Ching ; Weaver, W. Douglas ; Hochman, Judith S. ; Theroux, Pierre ; Rollins, Scott ; Todaro, Thomas G. ; Granger, Christopher B.

The American heart journal, 2006-04, Vol.151 (4), p.787-790 [Periódico revisado por pares]

New York, NY: Mosby, Inc

Texto completo disponível

Citações Citado por
5
Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial

Brener, Sorin J., MD ; Westerhout, Cynthia M., PhD ; Fu, Yuling, MD ; Todaro, Thomas G., MD ; Moliterno, David J., MD ; Wagner, Galen S., MD ; Granger, Christopher B., MD ; Armstrong, Paul W., MD

The American heart journal, 2009-11, Vol.158 (5), p.755-760 [Periódico revisado por pares]

New York, NY: Mosby, Inc

Texto completo disponível

Citações Citado por
6
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
Material Type:
Artigo 		Adicionar ao Meu Espaço

Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Ariti, Cono A., MSc ; Cleland, John G.F., MD ; Pocock, Stuart J., PhD ; Pfeffer, Marc A., MD, PhD ; Swedberg, Karl, MD, PhD ; Granger, Christopher B., MD ; McMurray, John J.V., MD ; Michelson, Eric L., MD ; Östergren, Jan, MD, PhD ; Yusuf, Salim, MD, DPhil

The American heart journal, 2011-11, Vol.162 (5), p.900-906 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por
7
Design and rationale of CURRENT-OASIS 7 : A randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy
Design and rationale of CURRENT-OASIS 7 : A randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Design and rationale of CURRENT-OASIS 7 : A randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy

MEHTA, Shamir R ; BASSAND, Jean-Pierre ; CHROLAVICIUS, Susan ; DIAZ, Rafael ; FOX, Keith A. A ; GRANGER, Christopher B ; JOLLY, Sanjit ; RUPPRECHT, Hans-Jurgen ; WIDIMSKY, Petr ; YUSUF, Salim

The American heart journal, 2008-12, Vol.156 (6), p.1080-1088 [Periódico revisado por pares]

New York, NY: Mosby

Texto completo disponível

Citações Citado por
8
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes

OASIS, Michelangelo

The American heart journal, 2005-12, Vol.150 (6), p.1107.e1-1107.e10 [Periódico revisado por pares]

New York, NY: Mosby, Inc

Texto completo disponível

Citações Citado por
9
Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy
Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy

Lockwood, Evan ; Fu, Yuling ; Wong, Brian ; Van de Werf, Frans ; Granger, Christopher B ; Armstrong, Paul W ; Goodman, Shaun G

The American heart journal, 2003-10, Vol.146 (4), p.640-645 [Periódico revisado por pares]

New York, NY: Mosby, Inc

Texto completo disponível

Citações Citado por
10
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview

Mahaffey, Kenneth W. ; Van de Werf, Frans ; Shernan, Stanton K. ; Granger, Christopher B. ; Verrier, Edward D. ; Filloon, Thomas G. ; Todaro, Thomas G. ; Adams, Peter X. ; Levy, Jerrold H. ; Hasselblad, Vic ; Armstrong, Paul W.

The American heart journal, 2006-08, Vol.152 (2), p.291-296 [Periódico revisado por pares]

New York, NY: Mosby, Inc

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.